Alzheimer’s disease has proved to be a daunting target for drug development, with a history of disappointing results in clinical trials for potential treatments from companies large and small.
Merck recently halted a late-stage trial of its promising Alzheimer’s disease drug — yet another blow to finding a therapy for this neurodegenerative disease. Eli Lilly, after all, ended a Phase 3 Alzheimer’s trial this past summer, which narrows the pool of advanced experimental drugs for the condition.
About the Author Reprints
